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Achievements and Limitations
of Antiretroviral Therapy
The development of combinations of
drugs that potently suppress HIV replica-
tion, collectively given the acronym
HAART (highly active antiretroviral ther-
apy), has transformed the lives of people
with HIV infection, particularly in high-
income countries [1]. Though modern
HAART regimens can drive HIV plasma
viral loads below the detection limits of
standard clinical assays ($50 copies HIV
RNA/ml), long-term treatment fails to
eradicate infectious virus as revealed by
the persistence of HIV proviral DNA and
infectious HIV in peripheral blood and
lymphoid tissue, as well as by low level
viremia (1–50 RNA copies/ml) in the
majority of treated people as detected by
ultrasensitive single copy assays [2–4].
Moreover, reservoirs of latently infected
resting memory CD4
+ T lymphocytes are
established early after infection and persist
throughout treatment with exceedingly
slow decay rates; these latent reservoirs
are unlikely to be eliminated by HAART
alone, and thus have the potential to re-
ignite the infection if activated after
therapy is halted. A further complication
is the existence of multiple sanctuaries of
infection in cell types from various lineages
(monocyte-macrophages, dendritic cells,
hemapoietic stem cells, etc.) detected in
distinct anatomical compartments (blood,
peripheral lymph nodes, gut mucosa,
central nervous system, genital tract,
etc.). These findings raise a number of
critical inter-related questions: Does the
extreme stability of the latently infected
cell reservoirs reflect simply the long
intrinsic half-life of memory CD4
+ T
lymphocytes, and/or are the reservoirs
continuously reseeded by low level ongo-
ing replication? To what extent does
residual viremia reflect incomplete sup-
pression of replication versus virus output
from stable (perhaps renewable) infected
cell reservoirs? What is the source(s) and
significance of intermittent viremia blips,
and from where does HIV rebound upon
cessation of HAART? Will deliberate
activation of resting CD4
+ T lymphocytes
under continued HAART provide a
clinical benefit by depleting latently infect-
ed cell reservoirs? While these issues
remain controversial, a major practical
consequence is irrefutable: cessation of
HAART results in rapid virus rebound, in
many cases to pre-treatment levels. As a
result, treatment must be long-term,
presumably for life.
A Renewed Focus on HIV
Eradication
The profound viral suppression achiev-
able with modern-day HAART regimens
coupled with the limitations and concerns
of prolonged treatment (cumulative side
effects, adherence difficulties, emergence
of drug resistance, high costs) have revi-
talized serious consideration of the pros-
pect for eradicating HIV from the body,
or at least of achieving a ‘‘functional cure’’
whereby therapy can be stopped without
viral rebound [3–9]. The latently infected
CD4
+ T cell reservoirs have generally
been viewed as the major obstacle to
eradication; hence there has been consid-
erable focus on therapeutic strategies to
drive the proviral genome out of latency,
including cytokines (e.g., IL-2), histone
deacetylase inhibitors (e.g., valproic acid,
SAHA), nontumorogenic phorbol esters
(e.g., prostratin), anti–T cell antibodies
(e.g., OKT3), and kinase agonists. It is
typically argued that augmenting HAART
with deliberate activation should result in
the eventual death of all productively
infected T cells by a combination of
natural mechanisms including viral cyto-
pathic effects, the inherently short life span
of activated T cells, and various immune
effector mechanisms. Yet to date, trials
testing of such approaches have shown no
clinical benefit, with at best a reduction in
the frequency of latently infected T cells in
a subset of patients [2–9]. Thus, clinical
trials based strictly on flushing out quies-
cent HIV to purge the infected cell
reservoirs have proven disappointing. Fur-
ther complicating the issue are recent
studies suggesting that in most patients,
the residual viremia is invariant and
genetically distinct from proviruses in
resting and activated CD4
+ T cells; this
has led to a hypothesis whereby most of
the residual viremia arises from a an
unknown cell type, perhaps a stem cell of
the monocyte-macrophage lineage, with
the capacity for proliferation and contin-
uous release of virus [4].
Rationale for Targeted
Cytotoxic Treatment as a
Complement to HAART
Whatever the source(s) and underlying
mechanism(s) for the persisting HIV, a
major point emphasized herein is that all
drugs in the current HAART arsenal
share one major feature: their efficacy
results from blocking specific steps of the
HIV replication cycle, thus preventing
new rounds of infection of naı ¨ve cells.
What they fail to do, at least directly, is to
kill cells that are already infected. The
theme to be developed here is straightfor-
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induced suppression of HIV replication
with a treatment that directly kills infected
cells? A direct means of achieving this is
based on display of the HIV envelope
glycoprotein (Env) on the external surface
of productively infected cells, where it can
be recognized by a specific binding
molecule such as an antibody or a soluble
fragment of the CD4 receptor. The Env-
targeting moiety can be linked to various
types of cytotoxic agents, yielding novel
molecules that selectively kill HIV-infected
cells. This ‘‘magic bullet’’ concept has
been prominent in the cancer field, with
consideration given to domains of protein
toxins, low MW cytotoxic molecules, and
radionuclides as alternative cytotoxic pay-
loads [10,11]. The first successes came a
decade ago, with the US Food and Drug
Administration’s approval of ONTAK
(IL-2 linked to the catalytic domain of
diphtheria toxin) for cutaneous T cell
lymphoma [12], and Mylotarg (a human-
ized anti-CD33 monoclonal antibody
linked to calicheamicin) for relapsing acute
myeloid leukemia in elderly patients [13].
The concept may have a particular
advantage for infectious diseases [14],
since the targeted molecule is encoded by
the pathogen, thereby minimizing side
effects encountered in anti-cancer applica-
tions associated with killing of normal cells
expressing low levels of the targeted
human antigen. Of course, selective killing
requires that the target antigen of the
infecting pathogen be expressed on the
surface of the infected cell, raising obvious
complexities for applications such as HIV
infection that are characterized by the
presence of latently infected cells.
Immunotoxin Approaches
against HIV in the Pre-HAART
Era
Not long after the recognition of the
retroviral nature of the AIDS etiologic
agent [15], several groups developed
cytotoxic agents targeted to HIV Env
using antibodies or soluble CD4 linked
biochemically or genetically to effector
domains of bacterial or plant protein
toxins [16–19]. Alternative strategies have
been considered whereby toxins are tar-
geted to cellular proteins endogenously
expressed on T cells, such as the IL-2
receptor on activated CD4
+ T lympho-
cytes [20–22] or CD45RO on memory T
cells [23].
Over the past two decades, our research
groups have collaborated to develop HIV
Env-targeted toxins based on Pseudomonas
aeruginosa exotoxin A (PE). Discrete struc-
tural domains within the linear sequence
of PE are associated with specific functions
[24]. This domain organization has been
exploited for cancer therapy by engineer-
ing recombinant immunotoxins in which
the native N-terminal cell binding domain
is replaced by an antibody fragment
(typically a single chain SCFv or a
disulfide-linked variable region construct)
directed against an antigen overexpressed
on the specific malignant cell type of
interest [25]. To apply this strategy to
HIV (Figure 1), we first designed
CD4(178)-PE40 (hereafter referred to as
CD4-PE) in which the targeting moiety is
the first two domains of CD4, which binds
directly to the gp120 subunit of Env [16].
Specific cytotoxicity against Env-express-
ing cells was demonstrated in two types of
in vitro systems: a) direct killing assays, in
which Env-expressing cells (either stable
transfectants or constitutively HIV-infect-
ed cell lines) were potently killed in dose-
dependent fashion, whereas the corre-
sponding parental cells lacking Env were
unaffected [16,26–28], and b) spreading
infection inhibition assays, in which infec-
tious HIV-1 is added to permissive target
cells, and virus production is measured
(p24 or reverse transcriptase) [27,29–32].
CD4-PE inhibited at concentrations where
minimal effects were observed with sCD4
(alone or linked to a PE moiety containing
an inactivating mutation), thereby demon-
strating that the observed activities were
due to selective killing of infected cells
rather than merely to virus neutralization
by the sCD4 moiety. Spreading infection
of primary isolates was inhibited [32–34]
in primary cell types especially relevant to
in vivo infection, i.e., peripheral blood
mononuclear cells and monocyte-derived
macrophages [31,32,34]. The latter are
particularly noteworthy in view of their
extremely low levels of surface Env, as well
as the postulated role of macrophages in
HIV persistence during HAART given
their relatively slow decay kinetics and
refractoriness to HIV-mediated cytopathic
effects [35,36].
Based on these promising in vitro
findings, CD4-PE was tested in Phase 1
clinical trials in the pre-HAART era
[37,38]. No antiviral or immune-enhanc-
ing effects were observed at the maximum
tolerated dose of 10–15 mg/kg, which was
well below the 40 mg/kg 63 doses typi-
cally given for PE-based cancer immuno-
toxins. The major dose-limiting toxicity
was reversible hepatocellular injury. These
disappointing results with CD4-PE greatly
diminished enthusiasm for immunotoxins
against HIV, and no additional clinical
trials have been conducted since.
Immunotoxin Approaches
against HIV: Why Now?
The failed clinical trials with CD4-PE
were conducted in the pre-HAART era
and thus essentially represented mono-
therapy (although some individuals also
received nucleoside reverse transcriptase
(RT) inhibitors that failed to suppress viral
loads [37]). The development of HAART
prompted us to suggest reconsideration of
the Env-targeted toxin concept [39]. In
the present report, we propose that
experimental and technical advances in
the ensuing decade have made this
argument even more compelling in several
critical ways: a) the persistence of HIV in
the face of highly suppressive HAART
reveals the need for approaches to aug-
ment the depletion of infected cell reser-
voirs, b) experiments in vitro and in
Figure 1. Schematic of Env-targeted toxins based on Pseudomonas exotoxin A. The
immunotoxins are based on the domain organization of native PE (top). The N-terminal segment
(domain I) is involved in binding to a surface receptor (members of the low density lipoprotein
receptor-related protein 1 family), the central region (domain II) facilitates membrane translocation of
the toxin into the cytoplasm, and the C-terminal segment (domain III) catalyzes ADP-ribosylation of
elongation factor 2, resulting in shut-down of protein synthesis and cell death. In the recombinant
single chain immunotoxins, domain I is replaced by a targeting moiety directed at HIV-1 gp120:
soluble CD4 first two domains (CD4-PE, middle), or the 3B3 SCFv (3B3-PE, bottom).
doi:10.1371/journal.ppat.1000803.g001
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immunotoxins have limited efficacy in
blocking spreading HIV infection when
used alone; however, they show dramatic
synergistic activities when used in combi-
nation with HIV replication inhibitors
(discussed below), c) new methods are
available to assess various efficacy param-
eters upon complementing HAART with
immunotoxins, d) clinical trials with PE-
based immunotoxins against certain leu-
kemias have shown impressive results
[40,41], and e) we have developed an
improved immunotoxin with greatly en-
hanced potency and minimal hepatoxicity
potential.
We designed a second PE-based immu-
notoxin, 3B3(Fv)-PE38 (hereafter referred
to as 3B3-PE) [27]. The targeting moiety is
the 3B3 SCFv, an affinity-maturated
variant of Fab b12 directed against the
highly conserved CD4 binding site on
gp120; compared to b12, 3B3 displays
improved binding affinity and greater
breadth of reactivity against Envs from
HIV-1 primary isolates [42]. We com-
pared the potencies of the two PE-based
immunotoxins in several in vitro systems.
In direct cell killing assays against Env-
expressing cell lines, 3B3-PE displayed
significantly enhanced potency (IC50
0.03–0.04 nM) compared to CD4-PE
(IC50 0.6–1.5 nM); neither agent was
cytotoxic against the corresponding Env-
negative cell lines [28]. Both immunotox-
ins inhibited spreading infection of all the
HIV-1 primary isolates tested (clade B),
again with 3B3-PE showing greater po-
tency than CD4-PE [43]. Like the original
immunotoxin, 3B3-PE inhibited HIV-1
spreading infection in monocyte-derived
macrophages. Most importantly, an ex-
tremely high intravenous dose of 3B3-PE
(250 mg/kg 63) caused no hepatotoxicity
in rhesus macaques, in contrast with the
elevation of serum hepatic enzymes in-
duced by CD4-PE at the same dosage
[43]. We had previously speculated [39]
that the dose-limiting hepatotoxicity ob-
served in the CD4-PE Phase 1 trials might
have been due to the CD4 moiety of the
chimeric toxin binding to free gp120
released from virions and infected cells,
leading to nonspecific liver uptake perhaps
via the asialoglycoprotein receptor on
hepatocytes recognizing oligosaccharide
chains on gp120. Subsequent studies argue
against this hypothesis. First, the distinct
macaque hepatotoxicity profiles noted
above (none for 3B3-PE; significant for
CD4-PE) have also been seen in simian
human immunodeficiency virus (SHIV)-
infected animals that expressed very high
viral loads (W. Wagner, M. G. Lewis, E.
A. Berger, and I. Pastan, unpublished
data); if hepatotoxicity reflected binding to
released gp120, both chimeric toxins
should have caused similar effects. Second,
animal studies with other PE-based im-
munotoxins have revealed that hepatoxi-
city is associated with a high isoelectric
point of the Fv [44]; the highly basic
nature of the CD4 moiety (isoelectric point
8.86) likely underlies the hepatotoxicity of
CD4-PE. We conclude that 3B3-PE is a
much more promising agent than CD4-
PE, with a significantly improved thera-
peutic window due to its enhanced specific
cytotoxic potency and greatly reduced
likelihood for dose-limiting hepatotoxicity.
Potent Synergy between
Immunotoxins and Inhibitors of
HIV Replication
Our cell culture studies demonstrated
significant activity of CD4-PE and 3B3-PE
against spreading HIV-1 infection. How-
ever, we observed limitations that we now
view as critical for our current thinking
about how immunotoxins should be con-
sidered for clinical use. First, while both
CD4-PE and 3B3-PE inhibited spreading
infection, the effects were relatively ineffi-
cient compared to activities in direct
killing assays; at best the viral peak was
reduced and delayed and the killing of
target cells was slowed, but the effects were
never complete [30,43]. Moreover, the
IC50 values in spreading infection assays
were significantly weaker than in direct
killing assays against target cells uniformly
expressing Env. These findings can be
readily understood in terms of the mode of
action of these agents; they cannot kill a
newly infected cell until surface Env is
expressed, by which time the virus infec-
tion has already begun to spread. There-
fore it can be predicted that the presence
of replication inhibitor would render
immunotoxin action more similar to what
is observed in direct killing assays, i.e.,
greater potency and complete activity.
Indeed, early cell culture studies showed
marked synergy between RT inhibitors
and CD4-PE, with the former agents
dramatically reducing the IC50 values of
the immunotoxin (and vice versa); combi-
nation treatment completely eradicated
HIV-1 from the culture [30]. Subsequent
experiments in the SCID-hu (thy,liv)
mouse model gave parallel results [45],
as shown in Figure 2. Combination of
replication inhibitors (zidovudine plus
lamivudine plus ritonavir) alone greatly
suppressed HIV levels in the human tissue
implant after a 30-day treatment period,
but the loads rebounded as measured at 30
days after cessation of treatment; CD4-PE
or 3B3-PE alone only minimally sup-
pressed viral loads at the end of the
treatment period, and at 30 days post-
treatment cessation. The results were
strikingly different with the combination
of HAART plus either CD4-PE or 3B3-
PE: viral loads were strongly suppressed
not only at the end of the 30-day
treatment period, but also at 30 days after
treatment cessation. These results high-
light the particular value of combining
HAART drugs, which potently block HIV
replication, with Env-targeted toxins,
which kill cells that are already infected.
The Way Forward
Based on the considerations outlined
above, we believe the time has come for
clinical trials of an Env-targeted cytotoxin
as a means to deplete infected cell
reservoirs persisting in the face of suppres-
sive HAART. This proposal differs funda-
mentally from HAART ‘‘intensification’’,
whereby a new HIV replication inhibitor
is added to an already suppressive antiret-
roviral regimen. Instead, it represents
‘‘complementation’’ of one class of agents
that blocks viral replication (HAART
drugs) with a second class that kills those
cells already infected (immunotoxin).
‘‘Proof-of-concept’’ preclinical studies
can be conducted in nonhuman primate
models of HIV therapy and persistence
[46–50]. Of particular interest is an Env-
SHIV model in which CD4
+ T lympho-
cytes are rapidly depleted, but high viral
loads are generated from infected tissue
macrophages that appear to be refractory
to the viral cytopathic effects and resistant
to the antiviral activity of the nucleoside
RT inhibitor PMPA [47]. Would immu-
notoxin treatment deplete this pool of
virus-producing cells? Perhaps more rele-
vant to conditions under which immuno-
toxins might be used in humans are the
recently developed chimeric SIVs harbor-
ing the HIV-1 reverse transcriptase (RT-
SHIVs) [46,48,49]. This model permits
testing of the same nucleoside and non-
nucleoside RT inhibitors currently used in
modern HAART regimens. However, the
SIV Envs in such SHIVs are not reactive
with the 3B3 antibody, thus precluding
analysis of 3B3-PE; the alternative CD4-
PE could be examined, since it is active
against SIV Envs [27] and would cause
negligible hepatotoxicity in macaques at
the doses that would be employed (40 mg/
kg, 63, unpublished data). While such
studies might prove interesting, it is
presently unclear whether any of the
macaque models will faithfully replicate
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humans, thus arguing against delaying
immunotoxin clinical trials until macaque
efficacy studies are performed.
3B3-PE is the agent of choice for Phase
1 clinical trials of immunotoxin comple-
mentation of HAART, due to its likely
improved therapeutic window compared
to CD4-PE. The most straightforward
approach would involve a one-two punch,
i.e., administration of 3B3-PE to patients
whose plasma viremia has been well
suppressed by HAART. Would persisting
HIV be lowered significantly, perhaps to
undetectable levels (unlike what has been
reported recently for residual viremia with
HAART intensification using additional
replication inhibitors [51], although con-
tradictory findings with the integrase
inhibitor raltegravir have been presented
recently [52,53])? The potential impact of
immunotoxin complementation is particu-
larly intriguing in view of the hypothesis
noted above that residual viremia may
derive predominantly from an unknown
cell type capable of proliferation and
continuous virus release [54,55]; immuno-
toxin treatment might be uniquely suited
to target such virus-producing cells. How-
ever, the fact that immunotoxin activity is
restricted to cells expressing surface Env is
almost certain to compromise its ultimate
efficacy in the context of persisting reser-
voirs of latently infected CD4
+ T cells.
Thus, durable benefits might require a
three-tiered attack, i.e., combining
HAART plus immunotoxin with a treat-
ment to deliberately trigger HIV expres-
sion from latent proviral genomes. In vitro
and ex vivo experiments have documented
the ability of CD4-PE [26] and 3B3-PE
[56] to selectively kill latently infected
CD4
+ T cells after induction of virus
expression; similarly, activating agents
have been shown to increase the immu-
notoxin susceptibility of cultured macro-
phages [57]. Given the limited under-
standing and conflicting viewpoints
regarding the mechanisms underlying
HIV persistence and rebound, we believe
it is essential to remain open-minded
regarding the testing of two-tiered versus
three-tiered approaches. In fact, augment-
ing HAART with candidate HIV-induc-
ing regimens and immunotoxins, separate-
ly and in combination, might provide
mutually informative insights. For exam-
ple, it is possible that an inducing regimen
deemed minimally effective in previous
clinical trials might have had benefits that
went unnoticed in the absence of targeted
killing of the newly activated infected cells;
conversely, the duration of immunotoxin-
mediated benefits might be negligible
without prior purging of latently infected
cells.
3B3-PE treatment will presumably be
limited to short periods (probably three
intravenous doses weekly for 1–2 weeks,
based on cancer protocols), since the
immunotoxin will likely elicit activity-
blocking antibodies against the highly
immunogenic PE moiety (as was observed
in the CD4-PE Phase 1 trial [37]). Should
promising results be obtained and addi-
tional treatment be desired, the potential
exists for switching to Env-targeted cyto-
toxins based on alternate bacterial or plant
protein toxin moieties as noted above, or
newly described agents employing low
molecular weight drugs [58] or radionu-
Figure 2. Effects of complementing HAART with Env-targeted toxins in thy/liv SCID-hu mouse model. Thy/liv-SCID-hu mice were
injected intraperitoneally with HIV and either left untreated (None) or immediately started on the indicated treatment. One month later, the left thy/
liv implants were biopsied, and viral loads were analyzed by quantitative coculture (open bars). Drug therapy was then stopped, and after 1 month
the left thy/liv implant of each mouse was rebiopsied and the viral load quantitated (filled bars). The data are presented as the TCID/10
6 thymocytes;
the mean values (6 SEM) were calculated for each group. Left panel, HAART (zidovudine+ lamivudine + ritonavir) or immunotoxins alone; right panel,
HAART alone compared to HAART plus immunotoxins. Data adapted from [45] ( 2000 by Goldstein et al.).
doi:10.1371/journal.ppat.1000803.g002
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Efforts to delete B cell epitopes from
PE38 [60] may also prove useful in this
context. Regarding enhancements and
variations of the targeting moiety, struc-
ture-based design has been used to im-
prove the potency of 3B3-PE [61]. How-
ever, it must be noted that not all HIV-1
primary isolates are susceptible to neutral-
ization by the 3B3 antibody [42]; thus, it
will be important to assess for each
potential clinical trial participant whether
their virus is recognized by 3B3 (using
virus and/or cells obtained from CD8-
depleted activated peripheral blood
mononuclear cells). The possibility must
also be considered for using alternate
immunotoxins containing different target-
ing moieties, such as those described
against gp41 [62,63] or new immunotox-
ins based on well-studied [64] or newly
described [65] broadly neutralizing mono-
clonal antibodies.
How might immunotoxin efficacy be
assessed? Beyond analysis of peripheral
blood (proviral DNA and infectious virus
in CD4
+ T cells; residual viremia detected
by single copy assay), the profound
involvement of gut-associated lymphoid
tissue during both acute HIV infection and
viral persistence under HAART [66]
highlights the critical importance of ex-
amining this compartment. Indeed, HIV
DNA levels have been shown to be highly
elevated in gut biopsy tissue compared to
those in peripheral blood from patients on
HAART [67].
Ultimately, immunotoxins will be of
value in HIV treatment only if they can
enable patients to stop HAART for
prolonged periods, sufficient to provide a
meaningful quality of life benefit. This is a
stringent demand in view of the ongoing
improvements in the efficacy and accept-
ability of antiretroviral drugs, and the risks
associated with intermittent cessation of
HAART [68]. The ultimate question
underlying the potential value of immu-
notoxins is: must every last infected cell in
the body be eliminated in order to achieve
a meaningful therapeutic benefit, or is it
possible that the infected cell load can be
reduced below a threshold such that
natural immune effector mechanisms,
perhaps enhanced by therapeutic vaccines,
can keep the infection in check without the
need for ongoing drug treatment? Only a
focused effort on clinical evaluation, with
all its associated complexities, will provide
an answer.
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